All News

PSS.scleroderma.arthritis.contractures

Autoantibody Associations in Systemic Sclerosis

Jack Cush, MD

Analysis of two large cohorts of systemic sclerosis (SSc) patients shows a signfiicant minority of patients to have autoantibodies typical of rheumatoid erosive arthrits, but their presence in SSc patients was associated with unique manifestations of SSc. 

Read Article
fever2.jpg

When to Stop Biologics in Systemic JIA?

Jack Cush, MD

Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations.

Read Article
keystone

RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone

Jack Cush, MD

Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.


Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

Janet Pope, MD, MPH, FRCPC

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
heel enthesitis spur calcaneal

Predicting RA, and Treatment of Subclinical Arthritis

Meral K. El Ramahi, MD, FACP, FACR

Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology. 

Read Article
Lab work

Infection or Disease Flare: What Tools Can Help Differentiate?

Olga Petryna, MD

Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult. Few studies have evaluated potential differentiators; and having such tools would meet a huge unmet need. 

Read Article
Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced. https://t.co/NczbrBXBl7 https://t.co/l93OM86qaX

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-35 (blood and urine) is elevated in #SLE pts with nephritis. Small study of 42 SLE pts serum IL-35 had 90% sensitivity & 65% specificity while urine IL-35 had 86.4% sensitivity and 75% specificity to establish the diagnosis of LN https://t.co/pK1rVCQQr9

Links:

Dr. John Cush RheumNow ( View Tweet)

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares Drs.Cush, Yusof, Mehta, Petryna and Tate review autoinflammatory data presented at #ACR21. @Yuz6Yusof @bella_mehta @DrPetryna @uptoTate https://t.co/oeAprkSBWZ https://t.co/1g9yRRFJqf

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr1908 Potential prognostic biomarker for lymphoma in #sjogren. ISG15 (IFN-I) expression was consistently ⬆️in pts with lymphoma vs none, both in blood and salivary gland biopsy. Work needed re: relation to other markers, ethnicity @RheumNow https://t.co/8VYYEXpXSw https://t.co/ZIkpx5kUfu

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo. Greatest in those with: 🔹+dsDNA 🔹low C3 or C4 🔹SLICC/ACR Damage index of 0 (argument for early treatment!) https://t.co/UcGXEklqwJ #ACR21 Abst#1295 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

AxSpA: Geographic Prevalence Association with HLA-B27: Dr. Rachel Tate ( @uptoTate ) Dr. Rachel Tate discusses abstract #0368 presented at the #ACR21 annual meeting. https://t.co/CnIjlWuKjZ https://t.co/vytIdK9CCo

Links:

Dr. John Cush RheumNow ( View Tweet)
Knowledge Bowl at #ACR21 ⭐️In a suspected PAN case, you order a peripheral smear to look for this potential etiology, ➡️Hairy cells @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to single measure in predicting incident gout over 9 years. Makes sense in general, maybe different in those with medication changes etc? Abstr#1449 #ACR21 @RheumNow https://t.co/69NofMNuB8
Richard Conway RichardPAConway ( View Tweet)
Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia ⭐️Anemia resolution associated with improved clinical status #ACR21 #ACRBest Abs#1331 @RheumNow https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Knowledge Bowl at #ACR21 ⭐️Which HLA allele confers an increased risk for anterior uveitis and inflammatory sacroillitis? ➡️HLA-B27 @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Knowledge Bowl at #ACR21 ⭐️This HLA allele can be seen in a certain vasculitis where panuveitis is a possibility and has a venulitis predilection ➡️HLA B51 @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Peripheral and axSpA pts with low Vitamin D levels (<30) had worse disease activity and functional impairment (BASDAI, ASDAS, BASFI) compared to pts with normal Vit D levels. Abs#1316 #ACR21 @RheumNow https://t.co/ulIqOAnWtp https://t.co/aMQaTpduJK

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow

Links:

Eric Dein ericdeinmd ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×